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Abstract: Multiple studies have reported inferior cosmetic outcomes after breast conservation 
surgery and adjuvant radiation therapy in black women. However, cosmetic analysis scales 
contemporarily utilized in the field of radiation oncology rely largely on subjective visual and 
tactile perception. These methods are undeniably fraught with intraobserver and interobserver 
variability. Herein, we uncover how and why these methods may unwittingly and disparately 
misjudge cosmetic outcomes in black women, and the clinical ramifications thereof. In addition, 
we highlight more objective cosmetic outcomes assessment programs that promise to yield more 
reproducible and unbiased results.
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Introduction
Breast conservation therapy, a treatment algorithm comprised of breast conservation 
surgery and radiation, has been established as standard of care for early-stage breast 
cancer, because it yields survival outcomes equivalent to mastectomy.1,2 The former 
approach affords breast   preservation which is cosmetically appealing to women. In the 
realm of breast conservation, there has been increasing focus on breast cosmesis over 
the past two decades. As such, there has been a plethora of studies published on cos-
metic outcomes following breast   conservation therapy. However, very few studies have 
reported on the cosmetic   outcomes in African American women after breast conservation 
therapy. Those that have, consistently report inferior outcomes in black women.
Tuamokumo et al reported their results of a matched-pairs analysis of 20 white and 
20 black women with early-stage breast cancer who underwent breast conservation ther-
apy.3 In this small study, the authors concluded that black women had worse cosmetic 
outcomes than white women. Deutsch and Flickinger4 and Taylor et al5 also reported 
significantly better cosmetic outcomes among white women than in black women. 
A more recent study by Vicini et al also reported that black women experienced less 
favorable cosmetic outcomes than white women after breast conservation therapy.6
In the aforementioned studies, conventional standard fractionation (using 22–25 
fractions of 200 cGy each) was employed. If the consensus is that black women reap 
inferior cosmetic benefits after breast conservation followed by standard fractionated 
radiation, radiobiological principles indicate that unconventional hypofractionated 
regimens using larger doses per fraction should yield worse cosmetic outcomes.7 On this 
premise, Canadian fractionation8 and accelerated partial breast irradiation,9 which pre-
scribe larger doses per fraction (16 fractions of 265 cGy and 10 fractions of 385 cGy, 





may therefore be reluctant to offer these options to black 
women. Such a de facto practice could have far reaching 
consequences.
Multiple studies have shown that underuse of and 
  noncompliance with adjuvant radiation is a grave problem 
in black women, contributing to inferior treatment out-
comes in this patient population.10–12 Some have cited the 
commitment to a 5–6-week course of radiation as one of 
the reasons for underutilization of radiation therapy.12,13 
Therefore, the option of a shortened course of radiation, 
such as Canadian fractionation (given over three weeks) or 
partial breast irradiation therapy (delivered over five days), 
when clinically appropriate, may be pivotal to improving 
underutilization of and noncompliance with adjuvant breast 
radiation in black women.
In the research to date, as in the majority of breast 
  conservation therapy studies, cosmetic outcomes and skin 
toxicities were largely determined by subjective methods. The 
Harvard National Surgical Adjuvant Breast and Bowel Project/
Radiation Therapy Oncology Group breast cosmesis grad-
ing scale is widely used in the assessment of cosmesis after 
breast conservation therapy.14 This instrument incorporates 
symmetry between breasts, skin pigmentation changes, scar 
appearance, and fibrosis. The extent of each feature is deter-
mined, and a cosmetic grade is assigned (Grade I excellent, 
Grade II good, Grade III fair, Grade IV poor). According to 
this scale, obvious skin color changes are assigned Grade IV . 
This method is entirely subjective because it relies on the 
evaluator to determine the severity of each cosmetic parameter 
by visualization only. In addition, the evaluator may be differ-
ent between patients and between consecutive assessments of 
the same patient. This introduces considerable interobserver, 
interpatient, and intrapatient variability, rendering the current 
visual methods poorly reproducible.
Hyperperception or 
hyperpigmentation?
As mentioned, pigmentation change is one of the parameters 
used to measure cosmetic outcomes after breast conservation 
therapy in the Harvard National Surgical Adjuvant Breast/
Bowel Project and Radiation Therapy Oncology Group 
cosmetic analysis tool.14 Skin pigmentation is mainly deter-
mined by two skin chromophores, ie, melanin and hemoglo-
bin (oxygenated and deoxygenated).15 Melanin, produced by 
melanocytes, is present in the basal layer of the epidermis. 
Hemoglobin is transported by blood vessels, which are 
abundant in the dermis. The number of melanocytes is not 
different between patients. However, darker-skinned indi-
viduals produce more melanin at baseline. Thus, in darker 
skin, the melanin pigment in the epidermis dominates, while 
in lighter skin, the pinkish color is a reflection of blood in 
the dermis.15
Oxyhemoglobin and deoxyhemoglobin absorb in the 
visible wavelength range of 520–610 nm and the near-
infrared wavelength range of 740–820 nm. Erythema is 
visualized as the sum of increased light absorption in the 
green (520–580 nm) and decreased light absorption in 
the red (600–700 nm) part of the spectrum. Melanin also 
absorbs strongly in the visible spectrum, and pigmentation is 
perceived as the increasing slope toward shorter wavelengths 
in the 620–700 nm region.16
Because of this overlap in absorption spectra, a   distinct 
contribution from each chromophore is difficult to   distinguish 
with the naked eye. For example, Matas et al found that 
erythema was not accurately perceived by visual techniques 
in dark-skinned individuals, leading to   incorrect determination 
of the blanch response used in the early detection and 
  diagnosis of pressure ulcers.17 Also, recent studies have shown 
that visual perception of erythema and pigmentation does not 
correlate with more quantitative measures.18
Because the visual perception of skin color is the 
cumulative result of contributions of all three optically active 
species, it should be possible to determine quantitatively 
the relative contributions of each chromophore, to quantify 
change in chromophore directly induced by radiation, and 
to determine the differences in radiation-induced change in 
pigmentation as a function of skin color.
One heavily explored method is analysis of the remit-
tance spectra of skin tissue utilizing diffuse reflectance 
spectroscopy.19 With this technique, apparent concentrations 
of melanin, oxyhemoglobin, and deoxyhemoglobin can be 
extracted from absorption spectra, thus separating changes 
in erythema and pigmentation, and dissecting out the relative 
chromophoric contributors to each skin reaction.
Although the field of dermatology has utilized these 
objective skin color measures for decades, radiation oncology 
has been slower to adopt such techniques. Currently, the 
existing cosmetic assessment tools depend solely on visual 
cues to determine changes in skin pigmentation during 
  radiation. With such a model, there may be a hyperbolic 
perception of pigmentation in darker-skinned women.
Objective methods for skin  
and cosmetic analysis
The last few years have heralded the advent of novel objective 
methods to measure skin pigmentation and cosmesis. Clinical, Cosmetic and Investigational Dermatology
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For example, skin analysis software developed by Konica 
Minolta for quantitative evaluation and analysis of skin 
color and pigmentation allows accurate measurements by 
  separately calculating the melanin index, hemoglobin index, 
and hemoglobin oxygen saturation index.20 This instrument 
uses diffuse spectroscopic reflectance as described earlier. 
One could envisage this program being used to assess changes 
in radiation-induced skin pigmentation objectively. A more 
comprehensive program, BCCT (Breast Cancer Conserva-
tive Treatment) core program described by Carduso et al 
incorporates several parameters related to asymmetry, color 
differences, and scar appearance, to quantify cosmetic out-
comes according to changes in pigmentation and breast sym-
metry.21 It is clear that these methods will be able to determine 
cosmetic outcomes after breast conservation therapy more 
objectively, concretely, and accurately.
As mentioned in the introduction to this commentary, 
there may be more than cosmesis at stake. Rather than 
propagating inferences based on subjective methods, it may 
be constructive to embrace more objective methods to better 
assess cosmetic outcomes, inform our clinical practice, and 
“diversify” our treatment recommendations.
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